Solventum to Report Fourth Quarter and Full Year Fiscal 2025 Earnings on February 26, 2026
Rhea-AI Summary
Solventum (NYSE: SOLV) will report fourth quarter and full year fiscal 2025 results on Thursday, Feb. 26, 2026 after U.S. market close. Management will host a webcast at 3:30 p.m. CST / 4:30 p.m. EST to discuss results and fiscal 2026 outlook.
A replay, press release, presentation slides and supplemental financial disclosures will be posted on the company Investor Relations website.
Positive
- None.
Negative
- None.
News Market Reaction – SOLV
On the day this news was published, SOLV gained 0.98%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
SOLV slipped 0.08% with mixed peer moves: several large med-tech peers (BAX, HOLX, COO, RMD) were modestly negative while WST gained 2.86%. No broad sector momentum or common news theme appears in the data.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 23 | Acquisition completion | Positive | -0.5% | Closed Acera Surgical acquisition with upfront and milestone-linked cash payments. |
| Dec 17 | Clinical guidance news | Positive | +0.9% | Published global ciNPT consensus and meta-analysis supporting reduced complications. |
| Dec 16 | Operational award | Positive | -0.8% | Earned HIRC Diamond Resiliency Badge for MedSurg supply chain strength. |
| Nov 25 | Conference participation | Neutral | -0.6% | Announced Piper Sandler healthcare conference fireside chat and webcast replay. |
| Nov 20 | Acquisition announcement | Positive | +2.9% | Agreed to acquire Acera Surgical to expand synthetic tissue matrices portfolio. |
Recent news shows mixed price reactions: strategic acquisitions and positive clinical/operational updates have sometimes aligned with the share move and sometimes seen mild divergence.
Recent news for Solventum includes two key Acera Surgical acquisition milestones in Nov–Dec 2025, one on agreement and one on completion, with differing short-term price reactions. Operational recognition (a HIRC resiliency badge) and clinical thought-leadership around ciNPT guidance and meta-analysis publication also featured, along with a conference appearance. Overall, the company has balanced portfolio expansion, operational strength, and medical evidence-building ahead of the newly announced Q4/FY 2025 earnings date.
Regulatory & Risk Context
An effective Form S-3ASR dated Aug. 13, 2025 registers up to 34,369,190 shares of Solventum common stock for resale by 3M Company. Solventum does not receive proceeds from these sales, but the filing highlights that future sales by 3M could adversely affect the market price. The registration remains effective under a Registration Rights Agreement through Aug. 13, 2027.
Market Pulse Summary
This announcement sets expectations for Solventum’s Q4 and full-year 2025 earnings release and webcast on Feb. 26, 2026, where management plans to discuss results and the fiscal 2026 outlook. In the months leading up to this, the company executed the Acera Surgical acquisition and reported significant balance-sheet changes in its Q3 2025 10-Q. Investors monitoring this event may focus on integration progress, capital allocation following prior deleveraging, and any commentary relevant to the existing S-3 resale registration by 3M.
AI-generated analysis. Not financial advice.
Earnings webcast details:
Date: | Thursday, Feb. 26, 2026 |
Time: | 3:30 p.m. CST / 4:30 p.m. EST |
Location: | |
+1 (800) 715-9871 | |
International dial-in: | +1 (646) 307-1963 |
Conference ID: | 6342275 |
A replay of the webcast, the earnings press release, presentation slides and supplemental financial disclosures will be available on the Investor Relations section of Solventum's website.
About Solventum
At Solventum, we enable better, smarter, safer healthcare to improve lives. As a new company with a long legacy of creating breakthrough solutions for our customers' toughest challenges, we pioneer game-changing innovations at the intersection of health, material and data science that change patients' lives for the better — while empowering healthcare professionals to perform at their best. See how at Solventum.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/solventum-to-report-fourth-quarter-and-full-year-fiscal-2025-earnings-on-february-26-2026-302676815.html
SOURCE Solventum
FAQ
When will Solventum (SOLV) release its fourth quarter and FY2025 earnings?
What time is the Solventum (SOLV) earnings webcast on Feb. 26, 2026?
How can investors access the Solventum (SOLV) Feb. 26 earnings webcast?
Will Solventum (SOLV) provide a replay and presentation materials after the Feb. 26 webcast?
What will Solventum (SOLV) management discuss during the Feb. 26 webcast?
